Cytokine Gene Polymorphisms support diagnostic monitoring of Romanian Multiple Myeloma patients by Banu, C et al.
Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011, pp.264‐268  
  © 2011, Carol Davila University Foundation
 
 
Cytokine Gene Polymorphisms support diagnostic monitoring of 
Romanian Multiple Myeloma patients 
 
Banu C*, Moise A** †, Arion CV*** †, Coriu D**** †, Tănase A**** and Constantinescu I** † 
*National Institute for Medical Assessment and Work Capacity Rehabilitation, Bucharest, Romania 
** Centre for Immunogenetics, Fundeni Clinical Institute, Bucharest, Romania 
*** Pediatrics Department, Fundeni Clinical Institute, Bucharest, Romania 
****Centre for Hematology and Bone Marrow Transplant,  
Fundeni Clinical Institute, Bucharest, Romania 
† “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania 
 
Correspondence to: Banu Cristina, MD 
National Institute for Medical Assessment and Work Capacity Rehabilitation, 
22 Panduri Av, Bucharest, Romania, 
Mobile: +40 723 337 175, Fax: +40 21 411 5125, E-mail:  krsbanu@yahoo.com 
 
Received: May 7th, 2011 – Accepted: July 4th, 2011 
 
 
Abstract: 
Introduction: cytokines and their receptor genes are very polymorphic. SNPs in the promotor region of the gene may 
influence the rate of cytokine secretion and may affect the biological activity of the encoded cytokine. A number of cytokines and 
cytokine receptors have been directly linked to the development of human cancers. The aim of our study was to determine the 
cytokine gene polymorphism in Romanian multiple myeloma patients.  
Material and methods: cytokine genotyping was performed in 80 patients and 100 healthy blood donors using molecular 
biology methods (SSP – Invitrogen, USA).  
Results: analyzing each polymorphic site, there was an increased frequency of the following genotypes in patients 
compared to control group: Interleukin-1beta (IL-1β) pos.+3962 TT, IL-12 pos.-1188 CC, gamma-Interferon (γ-IFN) pos.+874 AA, 
Transforming Growth Factor- beta1 (TGF- β1) codon10 TT, IL-2 pos.-330 TG and pos.+166 TT, Interleukin-4Receptor alpha (IL-4Rα) 
pos.-33 TC, IL-10 pos.-1082 GG and pos.-592 CC, IL-6 pos.-174 GG. It should be noted that almost one third of multiple myeloma 
patients had IL-6 pos.-174 GG genotype and 62% IL-10 GCC haplotype. These identified haplotypes are high interleukins producer, 
and this fact was confirmed by serum IL-6 and IL-10 levels performed by ELISA and enhanced chemiluminiscence methods.  
Conclusion: these markers could be successfully used, together with other specific clinical and biological parameters, as 
reliable individualized prognostic factors in multiple myeloma patients. 
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Introduction 
The cytokines and their receptor genes are very 
polymorphic. Single nucleotide polymorphisms (SNPs) in 
the promotor region of the gene may influence the rate of 
cytokine secretion and may affect the biological activity of 
the encoded cytokines. A number of cytokines and 
cytokine receptors have been directly linked to the 
development of human cancers [1].  
Multiple myeloma (MM) is a malignancy arising 
from post-germinal mature B cells characterized by an 
excess of monotypic plasma cells in the bone marrow 
secreting monoclonal immunoglobulins in the serum 
and/or urine, with a concomitant decrease in normal 
immunoglobulins and lytic bone lesions. Multiple myeloma 
is a clonal plasma cell neoplasm, which remains incurable 
despite conventional therapy. MM cells are predominantly 
localized in bone marrow (BM), and their interaction with 
bone marrow stromal cells (BMSCs) stimulates 
transcription and secretion of cytokines from BMSCs. 
Cytokines in turn not only promote the growth and survival 
of MM cells, but also reduce the efficacy of conventional 
drugs [2]. 
Plasma cells may produce Interleukin-6 (IL-6) by 
an autocrine mechanism whereas a paracrine mechanism 
is believed to be involved in the production of IL-6 by 
bone marrow stromal cells through an interaction between 
adhesion molecules present on myeloma plasma cells 
and their respective receptors that are present on bone 
marrow stromal cells [3]. In addition, control over 
production of IL-6 may be exerted by other interleukins 
such as Interleukin-1beta (IL-1β) and IL-10 [4]. Among 
target cells, the growth of normal and myeloma plasma 
cells is supported by IL-6, which also induces the Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
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differentiation of myeloma plasmablastic cells into mature 
plasma cells. 
Interleukin (IL)-10 is a critical cytokine involved in 
the terminal differentiation of B cells into plasma cells, but 
is also a growth factor of malignant plasma cells, 
produced by myeloma cells from about half the patients 
and is detected in the plasma of patients with plasma cell 
leukemia or solitary plasmacytoma. The myeloma cell 
growth activity of IL-10 is mediated through a gp130 
cytokine, oncostatin M (OSM) that is frequently produced 
by myeloma cells [5]. 
The aim of our study was to determine the cytokine gene 
polymorphism in Romanian multiple myeloma patients 
and if there is any correlation between certain genotypes, 
serum levels of cytokines and disease evolution and 
prognosis.  
Material and methods 
Eighty patients (F/M: 39/41) diagnosed with 
multiple myeloma and treated in Fundeni Clinical Institute, 
Department of Hematology between 2007 and 2011, and 
100 healthy blood donors were included in this study. 
Mean age of the patients was 59 years (36 – 79 years).   
The clinical manifestations of the onset of 
disease were highly variable, bone pain, secondary 
anemia and extramedullary infiltration being on the top 
(Table 1). 
Depending on the type of secreted 
immunoglobulin, distribution in the study group was the 
following (Table 2): 
  Most patients were in advanced stages of the 
disease (Table 3): 
  DNA was extracted from the whole peripheral 
blood by using Qiagen reagents. Cytokine genotyping 
was performed by Invitrogen™ Cytokine Genotyping Kit. 
The Invitrogen™ Cytokine Genotyping Kit is a PCR-based 
method designed to detect polymorphisms of thirteen 
cytokine genes. The kit consists of various formulations of 
lyophilized primer mixes that are used to amplify genomic 
DNA by using a 96 well thermal tray. After cycling is 
complete, the PCR products are loaded onto a 2% 
agarose gel for electrophoresis and then were visualized 
under UV illumination and documented by photography.  
 
Table 1: Clinical manifestations of disease onset 
Clinical 
manifestations 
Number 
of patients 
Frequency 
(%) 
Pain and bone lysis  59  73,75 
Secondary anemia  45  56,25 
Extramedullary 
infiltration  12  15 
Chronic renal failure  12  15 
Hemorrhagic syndrome  4  5 
Hyperviscosity 
syndrome  2  2,5 
Infectious syndrome  1  1,25 
Amyloidosis  1  1,25 
Smoldering  1  1,25 
 
 
Table 2: Multiple myeloma type 
Disease type 
Number  
of patients 
Frequency  
(%) 
Immunoglobulin G (IgG)  46  57,5 
Immunoglobulin A (IgA)  23  28,75 
Micromolecular k  5  6,25 
Micromolecular λ  3  3,75 
Non-secretory  3  3,75 
 
 
Table 3: Stages of disease 
Stages of disease  Number  
of patients 
Frequency  
(%) 
Stage    II A  30  37,5 
Stage    II B  4  5 
Stage   III A  33  41,25 
Stage   III B  14  17,5 
 
 
  In addition, to have a complete overview of the 
patients’ immunological status we have analyzed the 
association of cytokine gene polymorphisms with serum 
levels of cytokines (IL-6 and IL-10) measured by 
enhanced chemiluminescence (Immulite).  
  The Immulite System assay uses specific 
antibody or antigen, coated plastic beads as the solid 
phase, alkaline phosphatase labeled reagent and a 
chemiluminiscent enzyme substrate. After incubating the 
sample with the alkaline phosphatase reagent, the liquid 
reaction mixture, in the Test Unit, is rapidly separated 
from the bead when the bead is washed, and the Test 
Unit is spinned at a high speed on its vertical axis. The 
bead is left with no residual, unbound label. The bound 
label is then quantitated with a dioxetane substrate, which 
produces light. A photomultiplier tube detects light 266 
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Discussions 
Cytokines play a crucial role in the regulation of 
key pathways  of immunity, the balance between cell-
mediated (Th1) and humoral  (Th2) responsiveness. 
Genetic variation is common across the human genome. 
It is estimated that there are more than 7 million single 
nucleotide polymorphisms  (SNPs) with a minor allele 
frequency of 5% to 10%. Although most SNPs are not 
functionally important, there is a subset of variants that 
alter the expression or function of a gene product. Several 
studies have shown a link between polymorphisms in IL-
1β, IL-6, IL-10 and cancer risk. They may also be central 
to the pathogenesis of MM [7-9]. 
The interaction between the myeloma cell and 
the BM microenvironment is central to the growth and 
survival of myeloma cells. The myeloma cell adheres to 
the bone marrow (BM) microenvironment, and thereby 
stimulates angiogenesis and enhances the stimulation of 
cytokines such as IL-1β, IL-6 and IL-10 [10].  
In this study, we address the importance of the 
polymorphisms  IL-6 GC-174, IL-10  G-1082, C- 819, C- 
592,  which are known to affect the transcription levels of 
the genes and are also known to be important for cancer 
cell growth. 
There was no significant difference between 
patients and the control group on IL-6 -174 GG genotype 
frequency, but patients who showed this genotype, 
accompanied by increased serum levels of IL-6, had 
severe disease needing aggressive chemotherapy. 
On the other hand, IL-10 -1082GG genotype, 
was identified as being associated with a better overall 
survival of patients, together with the favorable prognostic 
factors. 
During the last decade, new treatments with 
immunomodulatory drugs and proteosome inhibitors have 
been introduced and have improved the patients’ survival. 
These drugs induce apoptosis of myeloma cells, interrupt 
the interaction between myeloma cells and stromal cells 
in the BM, inhibit angiogenesis and inhibit the secretion of 
IL-1β and IL-6. The treatment effects of the new drugs 
support the importance of these key regulators of the 
immune response in the pathogenesis of MM. Inborn 
genetic variation in these genes may therefore be 
important for the risk, prognosis and treatment outcome of 
MM. 
Conclusions 
  Our findings showed that in almost one third of 
the studied patients had IL-6 pos.-174 GG genotype and 
was associated with clinical and biological worsening of 
MM. IL-6 pos.-174 GG genotype was correlated with 
increased serum levels of IL-6 in some of the patients and 
in others with significantly high levels of IL-10. 
  64% of the multiple myeloma patients had IL-10 - 
GCC haplotype compare to the controls. 
  We conclude that these markers could be 
successfully used, together with other specific clinical and 
biological parameters, as reliable individualized 
prognostic factors in multiple myeloma patients. 
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